JoelYoungMD

Addiction, Forensic Psychiatry, Geriatric Psychiatry, Pain Medicine

Chief Medical Officer and Founder, Clinical Trials Group at the Rochester Center for Behavioral Medicine, Rochester Hills, MI

Join to view full profile

Dr. Young is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Young's full profile

Already have an account?

Office
441 South Livernois Road
100
Rochester, MI 48307
Phone+1 248-608-8800

Fax+1 248-608-2490
Is this information wrong?

Summary

Joel L. Young, MD is the Medical Director and Founder of the Rochester Center for Behavioral Medicine, and Clinical Associate Professor of Psychiatry at the Wayne State University School of Medicine. Dr. Young is certified by the American Board of Psychiatry and Neurology with added qualifications in geriatric, forensic and adolescent psychiatry.

Dr. Young is Chief Medical Officer of the Clinical Trials Group of Southeast Michigan. He has served as the primary investigator for more than 70 clinical trials, authoring over 100 articles, and the author of three books.

The Rochester Center for Behavioral Medicine

The Rochester Center for Behavioral Medicine brings together a team of over 60 mental health professionals with a wide variety of clinical backgrounds.

Education & Training

Wayne State University School of MedicineClass of 1989
University of MichiganBachelor of Arts Degree, College of Literature, Science, and the Arts, High Distinction, 1982

Certifications & Licensure

MI State Medical License Active through 2025
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Forensic Psychiatry
American Board of Psychiatry and Neurology Geriatric Psychiatry
American Board of Psychiatry and Neurology Board Certification
American Board of Psychiatry and NeurologyCertification, Forensic Qualifications
American Board of Psychiatry and NeurologyFellow

Awards, Honors, & Recognition

“Top Docs” in Psychiatry Hour Magazine
Outstanding Achievements in the Treatment of ADHD 3rd Annual Michael Golds Memorial Conference

Clinical Trials

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). Start of enrollment: 2012 Nov 01
Completed
Phase 4
A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Start of enrollment: 2021 Apr 27
Active, not recruiting
Phase 4
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome Start of enrollment: 2009 Nov 01
Completed
Phase 4
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms Start of enrollment: 2023 Apr 15
Recruiting
Not Applicable
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder Start of enrollment: 2009 Sep 01
Completed
Phase 2
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) Start of enrollment: 2014 Mar 01
Completed
Phase 2, Phase 3
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Start of enrollment: 2013 Nov 01
Completed
Phase 3
Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) Start of enrollment: 2010 Jun 01
Terminated
Phase 3
Switching to Iloperidone From Other Antipsychotics in Schizophrenia Start of enrollment: 2010 Aug 01
Completed
Phase 4
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder Start of enrollment: 2019 Oct 17
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Development and validation of the ADHD Symptom and Side Effect Tracking - Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations.
Joel L Young, Richard N Powell, Celeste Zabel, Jaime Saal, Lisa L M Welling, Jillian Fortain, Ashley Ceresnie> ;BMC Psychiatry. 2023 Nov 6
32 citations
Discontinuity in the transition from pediatric to adult health care for patients with attention-deficit/hyperactivity disorder.
C Brendan Montano, Joel Young> ;Postgraduate Medicine. 2012 Sep 1
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adult...
Stephen V. Faraone, Ann C. Childress, Steve Caras, Valerie Arnold, C. Brendan Montano, Elias H. Sarkis, Joel L. Young> ;The Journal of Clinical Psychiatry. 2021 Aug 24
19 citations
Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the DSM-5 Era.
Joel L. Young, David W. Goodman> ;The Primary Care Companion for CNS Disorders. 2016 Nov 17
4 citations
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo...
Linda Wietecha, David B. Clemow, Andrew S. Buchanan, Joel L. Young, Elias H. Sarkis, Robert L. Findling> ;CNS Neuroscience & Therapeutics. 2016 Jul 1
15 citations
Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.
Max E. Butterfield, Jaime Saal, Benjamin Young, Joel L. Young> ;Psychiatry Research. 2016 Feb 28
41 citations
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Timothy E. Wilens, Brigitte Robertson, Vanja Sikirica, Linda Harper, Joel L. Young, Ralph Bloomfield, Andrew Lyne, Gail Rynkowski> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2015 Nov 1
10 citations
Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form.
Joel Young, Thomas Rugino, Ryan Dammerman, Andrew Lyne, Jeffrey H. Newcorn> ;Journal of Child and Adolescent Psychopharmacology. 2014 Oct 1
28 citations
Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
Greg Mattingly, Richard H. Weisler, Joel Young, Ben Adeyi, Bryan Dirks, Thomas Babcock, Robert Lasser, Brian Scheckner, David W. Goodman> ;BMC Psychiatry. 2013 Jan 29
9 citations
Chronic fatigue syndrome: 3 cases and a discussion of the natural history of attention-deficit/hyperactivity disorder.
Joel L Young> ;Postgraduate Medicine. 2013 Jan 1
17 citations
Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled study
Joel L. Young> ;Psychiatry Research. 2013 May 15
8 citations
Delusional parasitosis in a female treated with mixed amphetamine salts: a case report and literature review.
Martha Buscarino, Jaime Saal, Joel L. Young> ;Case Reports in Psychiatry. 2012 Sep 5
3 citations
Siblings of adolescents with ADHD who themselves have ADHD are more likely to have psychiatric comorbidities than are unaffected siblings or controls without ADHD.
Joel L Young> ;Evidence-Based Mental Health. 2011 Nov 1
48 citations
Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
Joel L. Young, Elias Sarkis, Meihua Qiao, Linda Wietecha> ;Clinical Neuropharmacology. 2011 Mar 1
21 citations
Common comorbidities seen in adolescents with attention-deficit/hyperactivity disorder.
Julie Young> ;Adolescent Medicine. 2008 Aug 1
21 citations
Fibromylagia, chronic fatigue, and adult attention deficit hyperactivity disorder in the adult: a case study.
Joel L Young, Judith C Redmond> ;Psychopharmacology Bulletin. 2007 Jan 1
3 citations
Treatment of adult ADHD and comorbid disorders.
Joel L Young> ;CNS Spectrums. 2006 Oct 1
Join now to see all

Books/Book Chapters

Understanding and Treating Chronic Fatigue: A Practical Guide for Patients, Families, and Practitioners
Joel Young, MDPraeger2020
When Your Adult ChildWhen Your Adult Child Breaks Your Heart: Coping with Mental Illness Breaks Your Heart: Coping with Mental Illness
Joel L. Young, MDGlobe Pequot Lyons Press2013
Contemporary Guide to Adult ADHD
Joel L. Young, MDHandbooks in Healthcare2009
ADHD Grown Up: A Guide to Adolescent and Adult ADHD: A guide to adolescent and adult ADHD
Joel L. Young, MDW.W. Norton & Company, Inc.2007
Join now to see all

Authored Content

Monthly articlesJanuary 2020

Press Mentions

Virtual Therapy during the Coronavirus pandemic, and beyondAugust 17th, 2020
Looking Forward to 2022 Pt. II: Fibromyalgia and ME/CFS Clinical TrialsFebruary 6th, 2022
Three Generations of Health Care Heroes Inspired by Mildred Young Axelrod, M.D., School of Medicine Class of 1946May 28th, 2021
Join now to see all

Committees

Board Member, The State of Michigan, Quality Review Board on Psychostimulant Usage. 1997 - Present
Member, University of Michigan’s Health Systems Physician Advisory Council on Communication and Services 2006 - 2009
Member, Crittenton Hospital Executive Committee, Rochester, MI. 2000 - 2002
Chief of Staff, Department of Psychiatry, Crittenton Hospital. 2000 - 2002

Professional Memberships

American Medical Association - AMA
Member
American Psychiatric Association - APA
Member
Michigan Psychiatric Society
Member
Michigan State Medical Society
Member
American Society of Clinical Psychopharmacology
Member
Association of Clinical Research Professionals
Member
American Academy of Psychiatry and the Law - AAPL
Member
United Physicians Group
Member

External Links

Facebookhttps://www.facebook.com/RCBM-106854299348530/
LinkedInhttps://www.linkedin.com/company/rochester-center-for-behavioral-medicine/about/
LinkedInhttps://www.linkedin.com/in/joel-young-md-a9906114/